Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC) Meeting Abstract
| Authors: | Rudin, C. M.; Pietanza, M. C.; Bauer, T. M.; Spigel, D. R.; Ready, N.; Morgensztern, D.; Glisson, B. S.; Byers, L. A.; Johnson, M. L.; Burris, H. A.; Robert, F.; Strickland, D. K.; Zayed, H.; Govindan, R.; Dylla, S.; Peng, S. L. |
| Abstract Title: | Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC) |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 18 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-06-20 |
| Start Page: | 752s |
| Language: | English |
| ACCESSION: | WOS:000443264100018 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2016.34.18_suppl.LBA8505 |
| Notes: | Meeting Abstract: LBA8505 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work